Fluorobis(phenylsulfonyl)methane: A fluoromethide equivalent and palladium-catalyzed enantioselective allylic monofluoromethylation

Angewandte Chemie - International Edition

Volumn 45, Issue 30, 2006, Pages 4973-4977

  Fukuzumi, Takeo ^a   Shibata, Norio ^a   Sugiura, Masayoshi ^a   Yasui, Hiroyuki ^a   Nakamura, Shuichi ^a   Toru, Takeshi ^a  

^a NAGOYA INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Asymmetric synthesis; Drug design; Fluorine; Fluoromethylation; Palladium

Indexed keywords

ASYMMETRIC SYNTHESIS; DRUG DESIGN; FLUOROMETHYLATION; MONOFLUOROMETHYLATION;

CATALYSIS; FLUORINE; ISOMERS; PALLADIUM; REACTION KINETICS; SYNTHESIS (CHEMICAL);

METHANE;

ALLYL COMPOUND; FURAN DERIVATIVE; IBUPROFEN; METHANE; ORGANOMETALLIC COMPOUND; PALLADIUM;

ARTICLE; CATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STEREOISOMERISM; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

ALLYL COMPOUNDS; CATALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLOGRAPHY, X-RAY; FURANS; IBUPROFEN; METHANE; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; PALLADIUM; STEREOISOMERISM;

EID: 33746672640     PISSN: 14337851     EISSN: None     Source Type: Journal    
DOI: 10.1002/anie.200600625     Document Type: Article

References (75)

1. a) Biomedicinal Aspects of Fluorine Chemistry (Eds.: R. Filler, Y. Kobayashi), Elsevier Biomedical Press and Kodansha Ltd, New York, 1982;
2. b) "Biomedical Frontiers of Fluorine Chemistry": ACS Symp. Ser. 1996, 639;
3. c) Organofluorine Compounds in Medicinal Chemistry and Biomedical Applications (Eds.: R. Filler, Y. Kobayashi, L. M. Yagupolskii), Elsevier, Amsterdam, 1993.
4. a) Enantiocontrolled Synthesis of Fluoro-Organic Compounds: Stereochemical Challenges and Biomedical Targets (Ed.: V. A. Soloshonok), Wiley, Chichester, 1999;
5. b) "Asymmetric Fluoroorganic Chemistry. Synthesis, Applications, and Future Directions": ACS Symp. Ser. 2000, 746;
6. c) R. D. Chambers, Fluorine in Organic Chemistry, Blackwell Publishing, Oxford, UK, 2004;
7. d) P. Kitsch, Modern Fluoroorganic Chemistry, Wiley-VCH, Weinheim, 2004.
8. a) H. Ibrahim, A. Togni, Chem. Commun. 2004, 1147-1155;
9. b) J.-A. Ma, D. Cahard, Chem. Rev. 2004, 104, 6119-6146;
10. c) G. K. S. Prakash, A. K. Yudin, Chem. Rev. 1997, 97, 757-786;
11. d) After submission of this manuscript, the diastereoselective nucleophilic monofluoromethylation of imines with fluoromethyl phenyl sulfone was described: Y. Li, C. Ni, J. Liu, L. Zhang, J. Zheng, L. Zhu, J. Hu, Org. Lett. 2006, 8, 1693-1696.
12. a) Fusso Yakugaku (Eds.: Y. Kobayashi, I. Kumadaki, T. Taguchi), Hirokawa, Tokyo, 1992;
13. b) Organofluorine Chemistry: Principles and Commercial Applications (Eds.: R. E. Banks, B. E. Smart, J. C. Tatlow), Plenum, New York, 1994, chap. 3;
14. c) B. E. Smart, J. Fluorine Chem. 2001, 109, 3-11.
15. a) G. W. Gribble, J. Chem. Educ. 1973, 50, 460-462;
16. b) R. Peters, R. W. Wakelin, Proc. R. Soc. London Ser. B 1953, 140, 497-507;
17. c) E. Kun, R. J. Dummel, Methods Enzymol. 1969, 13, 623-672.
18. a) D. O'Hagan, H. S. Rzepa, Chem. Commun. 1997, 645-652;
19. b) J. Kollonitsch in Biomedicinal Aspects of Fluorine Chemistry, (Eds.: R. Filler, Y. Kobayashi), Elsevier Biomedical Press and Kodansha Ltd, New York, Tokyo, 1982, pp. 93-122;
20. c) R. H. Abeles, A. L. Maycock, Acc. Chem. Res. 1976, 9, 313-319;
21. d) R. B. Silverman, S. M. Nanavati, J. Med. Chem. 1990, 33, 931-936;
22. e) J. Kollonitsch, A. A. Patchett, S. Marburg, A. L. Maycock, L. M. Perkins, G. A. Doldouras, D. E. Duggan, S. D. Aster, Nature 1978, 274, 906-908.
23. a) N. Shibata, J. Kohno, K. Takai, T. Ishimaru, S. Nakamura, T. Toru, S. Kanemasa, Angew. Chem. 2005, 117, 4276-4279;
24. Angew. Chem. Int. Ed. 2005, 44, 4204-4207;
25. b) N. Shibata, E. Suzuki, Y. Takeuchi, J. Am. Chem. Soc. 2000, 122, 10 728-10 729;
26. c) N. Shibata, E. Suzuki, T. Asahi, M. Shiro, J. Am. Chem. Soc. 2001, 123, 7001-7009;
27. d) N. Shibata, T. Ishimaru, E. Suzuki, K. L. Kirk, J. Org. Chem. 2003, 68, 2494-2497;
28. e) N. Shibata, T. Ishimaru, T. Nagai, J. Kohno, T. Toru, Synlett 2004, 1703-1706;
29. f) N. Shibata, T. Ishimaru, M. Nakamura, T. Toru, Synlett 2004, 2509-2512;
30. g) N. Shibata, T. Tarui, Y. Doi, K. L. Kirk, Angew. Chem. 2001, 113, 4593-4595;
31. Angew. Chem. Int. Ed. 2001, 40, 4461-4463; .
32. a) G. K. S. Prakash, J. Hu, G. A. Olah, J. Org. Chem. 2003, 68 4457-4463;
33. b) Y. Li, J. Hu, Angew. Chem. 2005, 117, 6032-6036;
34. Angew. Chem. Int. Ed. 2005, 44, 5882-5886.
35. S. Nakamura, T. Fukuzumi, T. Toru, Chirality 2004, 16, 10-12.
36. a) L. Acemoglu, J. M. J. Williams, J. Mol. Catal. A 2003, 196, 3-11;
37. b) B. M. Trost, M. L. Crawley, Chem. Rev. 2003, 103, 2921-2944
38. ; c) P. V. Matt, A. Pfaltz, Angew. Chem. 1993, 105, 614-615;
39. Angew. Chem. Int. Ed. Engl. 1993, 32, 566-568;
40. d) J. Sprinz, G. Helmchen, Tetrahedron Lett. 1993, 34, 1769-1772;
41. e) G. J. Dawson, C. G. Frost, J. M. J. Williams, S. J. Coote, Tetrahedron Lett. 1993, 34, 3149-3150;
42. f) B. M. Trost, D. L. V. Vranken, C. Bingel, J. Am. Chem. Soc. 1992, 114, 9327-9343.
43. a) See the Supporting Information,
44. b) A typical experimental procedure is given in the Supporting Information.
45. H. J. Castejon, K. B. Wiberg, J. Org. Chem. 1998, 63, 3937-3942.
46. a) The reaction mechanism is discussed in the Supporting Information,
47. b) Absolute stereochemistries were assigned by X-ray crystallographic analysis (for 3d, see the Supporting Information) or tentatively determined by comparing the optical rotations of 3a and 3b with those of their non-fluorinated derivatives (see the Supporting Information);
48. c) Enantiomeric excesses of 3g,h were determined by HPLC analysis using CHIRALCEL OD-H. The absolute stereochemistry of 3g was assigned based on the proposed reaction mechanism (see reference [10b, f] and the Supporting Information) and tentatively determined by comparing the optical rotation with that of β-D-carbaribofuranose after chemical derivatization of 3g to 5-deoxy-5-fluoro-β-D-carbaribofuranose (5) (see Scheme 3).
49. H. Hao, G. Wang, J. Sun, Drug Metab. Rev. 2005, 37, 215-234.
50. a) O. Goj, S. Kotila, G. Haufe, Tetrahedron 1996, 52, 12 761-12 774;
51. b) W. J. Middleton, E. M. Bingham, J. Fluorine Chem. 1983, 22, 561-574;
52. c) Y. Yamazaki, S. Yusa, Y. Kageyama, H. Tsue, K. Hirao, H. Okuno, J. Fluorine Chem. 1996, 79, 167-171;
53. d) M. Schlosser, D. Michel, Z. Guo, C. J. Sih, Tetrahedron 1996, 52, 8257-8262;
54. e) M. Villa, N. J. Smeyers, M. -L. Senent, Y. G. Smeyers, THEOCHEM 2001, 537, 265-269;
55. f) Y. Takeuchi, H. Fujisawa, T. Fujiwara, M. Matsuura, H. Komatsu, S. Ueno, T. Matsuzaki, Chem. Pharm. Bull. 2005, 53, 1062-1064.
56. Other monofluoromethylarylpropionic acid derivatives besides 4 have been reported: a) D. Haigh, L. J. Jefcott, K. Magee, H. McNab, J. Chem. Soc. Perkin Trans. 1 1996, 2895-2900;
57. b) M. C. Lu, L. B. Shih, H. S. Jae, J. E. Gearien, E. B. Thompson, J. Med. Chem. 1987, 30, 424-427;
58. c) S. Hamman, C. G. Beguin, Tetrahedron Lett. 1983, 24, 57-60;
59. d) J. Barker, R. Keck, J. Rétey, Tetrahedron Lett. 1982, 23, 1549-1552;
60. e) F. Faustini, S. D. Munari, A. Panzeri, V. Villa, C. A. Gandolfi, Tetrahedron Lett. 1981, 22, 4533-4536;
61. f) G. A. Olah, G. K. S. Prakash, Y. L. Chao, Helv. Chim. Acta 1981, 64, 2528-2530;
62. g) R. Keck, J. Rétey, Helv. Chim. Acta 1980, 63, 769-772;
63. h) Y. Yamazaki, S. Yusa, Y. Kageyama, H. Tsue, K. Hirao, H. Okuno, J. Fluorine Chem. 1996, 79, 167-171.
64. 30 = + 60 (c = 2 in EtOH), see D. G. Kaiser, G. J. Vangiessen, R. J. Reischer, W. J. Weckter, J. Pharm. Sci. 1976, 65, 269-273.
65. For example: a) M. T. Crimmins, Tetrahedron 1998, 54, 9229-9272;
66. b) E. De Clercq, Nucleosides Nucleotides 1998, 17, 625-634;
67. c) V. E. Marquez, Adv. Antiviral Drug Des. 1996, 2, 89-146;
68. d) T. S. Mansour, R. Storer, Curr. Pharm. Des. 1997, 3, 227-264;
69. e) G. Rassu, L. Auzzas, L. Pinna, V. Zambrano, L. Battistini, F. Zanardi, L. Marzocchi, D. Acquotti, G. Casiraghi, J. Org. Chem. 2001, 66, 8070-8075.
70. For example: a) P. Hadwiger, P. Mayr, B. Nidetzky, A. E. Stütz, A. Tauss, Tetrahedron: Asymmetry 2000, 11, 607-620;
71. b) C. Schaffrath, S. L. Cobb, D. O'Hagan, Angew. Chem. 2002, 114, 4069-4071;
72. Angew. Chem. Int. Ed. 2002, 41, 3913-3915;
73. c) E. P. J. Boot, G. A. Koning, G. Storm, J. P. A. Wagenaar-Hilbers, W. van Eden, L. A. Everse, M. H. M. Wauben, Arthritis Res. Ther. 2005, 7, R604-R615.
74. I. Das, T. Pathak, Org. Lett. 2006, 8, 1303-1306.
75. 20 = + 10.0 (c = 1.1 in MeOH). See reference [18e].